Technology area: Communications
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Liqbio Biomedical Company Limited manages a patent portfolio in the Communications technology area. There is 1 pending office action currently active for the company. This single matter is handled by 1 distinct examiner and is located within 1 distinct art unit. This structure reflects a very specific technical focus for the company's current patent applications.
MICHAEL ROBERT CAMMARATA is the busiest examiner for the portfolio, currently managing 1 pending office action. With only 1 distinct examiner involved in the company's filings, the prosecution is highly concentrated. The 1 distinct art unit suggests that the company's technical claims are being reviewed by a single specialized team at the patent office. This centralization, involving 1 distinct examiner for the 1 pending office action, may provide a more predictable environment for negotiating the scope of the company's communications patents.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CAMMARATA, MICHAEL ROBERT | 1 | 69.8% | +34.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18752714 | CORRECTION AND CAPTURE METHOD FOR BIOLOGICAL PARTICLE CAPTURE DEVICE | CAMMARATA, MICHAEL ROBERT | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18752714 | CORRECTION AND CAPTURE METHOD FOR BIOLOGICAL PARTICLE CAPTURE DEVICE | CAMMARATA, MICHAEL ROBERT | — |
| Art Unit | Apps |
|---|---|
| 2667 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18752714 | CORRECTION AND CAPTURE METHOD FOR BIOLOGICAL PARTICLE CAPTURE DEVICE | CAMMARATA, MICHAEL ROBERT | 2667 | §103§112 | Final Rejection | — | Pending | Jun 24, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLiqbio Biomedical Company Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Michael Robert Cammarata has the most, with 1 of Liqbio Biomedical Company Limited's pending office actions.
Mostly Communications (USPTO Tech Center 2600), based on where its pending office actions are examined.
